“…In another article in this issue, Rivera-Toquica et al [4] used Colombian Heart Failure Registry (RECOLFACA) data to investigate compliance with GDMT in the treatment of HFrEF. They found that ACEIs or ARBs were prescribed to 72.3% of patients with HFrEF, β-blockers to 88.9%, MRAs to 67.9%, and ARNIs to 13.1%.…”